[ad_1] Collaboration builds clinical foundation for GNX1021, a first-in-class glycan-directed ADC being developed for gastric cancer patients  NEW TAIPEI CITY, Taiwan, Nov. 24, 2025 /PRNewswire/ — GlycoNex, Inc. (4168, hereinafter referred to as GNX), a […]

[ad_1] Sterling to Manufacture GNX102-ADC for Planned Phase 1 Clinical Program NEW TAIPEI CITY, Taiwan, Nov. 12, 2024 /PRNewswire/ — GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on […]